{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:10:57Z","timestamp":1790683857729,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI104681"],"award-info":[{"award-number":["UM1AI104681"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.idcr.2024.e02138","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:50:04Z","timestamp":1735087804000},"page":"e02138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Fever for days: A challenging case of dalbavancin-induced fever"],"prefix":"10.1016","volume":"39","author":[{"given":"Mohamed A.","family":"Almahal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2834-3972","authenticated-orcid":false,"given":"Benjamin","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-1533","authenticated-orcid":false,"given":"Sarah","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-4871","authenticated-orcid":false,"given":"Ahmed","family":"Babiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.idcr.2024.e02138_bib1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14740338.2021.1935864","article-title":"Systematic review and meta-analysis on the safety of dalbavancin","volume":"20","author":"Monteagudo-Mart\u00ednez","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.idcr.2024.e02138_bib2","unstructured":"Administration US FDA. Drug Trials Snapshot DALVANCE (dalbavancin) 2021."},{"issue":"8","key":"10.1016\/j.idcr.2024.e02138_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa293","article-title":"Use of a standardized dalbavancin approach to facilitate earlier hospital discharge for vulnerable patients receiving prolonged inpatient antibiotic therapy","volume":"7","author":"Vazquez Deida","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.idcr.2024.e02138_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","article-title":"Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies","volume":"39","author":"Dunne","year":"2016","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.idcr.2024.e02138_bib5","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/jac\/dkaa188","article-title":"Dalbavancin for the management of osteomyelitis: a major step forward?","volume":"75","author":"Almangour","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idcr.2024.e02138_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.idcr.2024.e02138_bib7","first-page":"82","article-title":"Evaluation of dalbavancin alone and in combination with \u03b2-lactam antibiotics against resistant phenotypes of Staphylococcus aureus","volume":"74","author":"Xhemali","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idcr.2024.e02138_bib8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idcr.2024.e02138_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"23","key":"10.1016\/j.idcr.2024.e02138_bib10","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.idcr.2024.e02138_bib11","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"issue":"8","key":"10.1016\/j.idcr.2024.e02138_bib12","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.jaip.2021.04.013","article-title":"Considerations for cross-reactivity between vancomycin and other glycopeptides","volume":"9","author":"Nakkam","year":"2021","journal-title":"J Allergy Clin Immunol Pr"},{"issue":"12","key":"10.1016\/j.idcr.2024.e02138_bib13","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clinthera.2022.11.006","article-title":"Evaluation of dalbavancin in vancomycin allergic patients: a case series","volume":"44","author":"Jones","year":"2022","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.idcr.2024.e02138_bib14","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.anai.2016.03.030","article-title":"Immune-mediated reactions to vancomycin: a systematic case review and analysis","volume":"116","author":"Minhas","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.idcr.2024.e02138_bib15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamainternmed.2020.0403","article-title":"Development and validation of a penicillin allergy clinical decision rule","volume":"180","author":"Trubiano","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.idcr.2024.e02138_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13601-016-0138-3","article-title":"Three cases of anaphylaxis following injection of a depot corticosteroid with evidence of IgE sensitization to macrogols rather than the active steroid","volume":"7","author":"Brandt","year":"2017","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"10.1016\/j.idcr.2024.e02138_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","article-title":"Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial","volume":"23","author":"Turner","year":"2022","journal-title":"Trials"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250924002142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250924002142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T05:56:22Z","timestamp":1744523782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250924002142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":17,"alternative-id":["S2214250924002142"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2024.e02138","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fever for days: A challenging case of dalbavancin-induced fever","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2024.e02138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e02138"}}